Endocrine Abstracts

20th European Congress of Endocrinology
19–22 May 2018

EDITORS
The abstracts were marked by the Abstract marking Panel selected by the programme Organising Committee

Programme Organising Committee

Marta Karotkin (UK) Chair
Barbara Obermayer-Pietro (Austria) Co-chair
Rafael M. Luque (Spain) Co-chair
Manel Puig Domingo (Spain) EDC chair

Anders Sundin (Sweden)
Andrew Arden (UK)
Camilla Schalin-Jiuntti (Finland)
Carlo Acertini (UK)
Cesar Luiz Bogusiewski (Brazil)
Claudio Marcocci (Italy)
Cynthia Andoniadou (UK)
Dafne Karalos (Greece)
Djuro Macic (Serbia)
Gérald Ravère (France)
Guillaume Assie (France)
Jens Otto Lunde Jørgensen (Denmark)
José Köhrle (Germany)
Ljiljana (Serbia)

Local Organising Committee

Manuel Puig Domingo (Spain) LOC chair
Javier Salvador (Pamplona)
Felix Casasnuera (Santiago de Compostela)
Juan Bernal (Madrid)
Antonio Picó (Alicante)
Mónica Miramuriet (Madrid)
Pilar Sasturibar (Madrid)

Abstract Marking Panel

C Acerini UK
M Alevizaki Greece
N Alonso
C Alvarez
C Andoniadou
W Adh UK
G Assist France
S Babuskou France
K Badenhoop Germany
P Beck-Peccor Italy
J Berraert France
F Beuschlein Germany
C Besau UK
H Bierermann Germany
K Bolderdiet UK
h Boesen The Netherlands
G Brabant Germany
M L Brandi Italy
K Briot France
M Brown UK
C Buchanan UK
P Burman Sweden
S Canavaro Italy
J Cap Czech Republic
J S Carroll UK
J Castano Spain
P Chassagne France
F Chiarelli Italy
I Chiodini Italy
J Chowen Spain
T Coll UK
C Daru UK
M Dattani UK
C Dayan UK
W de Herder Netherlands
W Diholo UK
G Di Dalmau Germany
J Dreux Canada
I Duntas Greece
S Duran
G Eisenhofer Germany
F Fallo
M Fastenacht Germany
R Fearon The Netherlands
U Feld-Rasmussen Denmark
F Flamant France
E Fliers The Netherlands

C Follon Sweden
S Franks UK
W Fraser UK
J Frestyk Denmark
I Fugazzolla Italy
F Gabakis Czech Republic
F Giorgino Italy
N Chyan
J Gomes-Ambrosio Spain
R Granata Italy
J Grossi Germany
A Grossman UK
R Hamp Czech Republic
M Haukkainen Finland
A Hoeflich Germany
W Hoffer UK
J Hultenemi UK
E Husselbye
F Ignat Hungary
I Iovskaya Russia
T Isadovic
F I. Ionescu Serbia
M.L. Jaffrain-Rea Italy
B Jasna Poland
J Jevcak Slovakia
A Kalheuk Netherlands
G Kolias Greece
A Karfsson Sweden
M Keil USA
F Kellestimur Turkey
R Kinsman USA
M Korbents UK
B Kos-Kudla Poland
N Krone UK
M Kruck Czech Rep
H Krude Germany
M Luan Germany
P Lukasov Hungary
E Lalli
J Larsen The Netherlands
G Laszlo UK
T Lanks The Netherlands
P Lips Netherlands
S Llachana UK
M Lopez Spain
A Luz Austria
C Luis Bogusiewski Brazil
R M Luque Spain
M Luster Germany
D Macit Serbia
A Maggi Italy
M Maggi Italy
M Mannelli Italy
F Mantero Italy
JP Martinez-Barbera
L Massip Italy
G Mastorakos Greece
D Mauricio
C McCabe UK
R Mitchell UK
J Mittag
L Morris-Papunen Finland
N Mortin UK
A Munkjorde UK
E Nagy Hungary
J Newell-Price UK
B Obermayer-Pietro Austria
P Olivera Portugal
U Pajotti Italy
S Pappopulos Netherlands
R Peters The Netherlands
L Persi Italy
M Pfleger Slovenia
P Pfeffer Germany
V Piraugs Latvia
M Pustanen Finland
D Power Portugal
V Puyot France
M Puig Domingo Spain
S Radun UK
N Rahman Finland
B Rainey USA
E Raipert-De Meets Denmark
G Raventor France
M Reisiecka Germany
J Reverchon
S Rice UK
G Risco-Inaquiere
M Robledo Spain
P Rodgers France
H Romijn The Netherlands
C Ronchi Italy
G P Rossi
M Ruchala Poland
E Rutter Belgium
P Saunders UK
S Schmidt Germany
P Scholffki Belgium
J Schoppel Germany
R Simpel UK
M Simon Italy
U Smith Sweden
A Sippola
G Stalla Germany
C Stratakis UK
T Tankova Bulgaria
M Terao-Sempere
M Terezo
M Theodoropoulos Germany
C Thompson Ireland
P Thompson UK
V Tillmanns Estonia
M Torn Hungary
S Tsatsakis Greece
A Tuasp Greece/UK
M Tsirula Greece
E Valassi Poland
E van den Akker Netherlands
A van der Klauwe UK
A J van der Lelj Netherlands
J van Eck The Netherlands
W van Hal Belgium
L van Rossum Netherlands
B Verges France
J Verhoeven The Netherlands
P Vitt Italy
V Volke Estonia
R Voutilainen Finland
I Wilkinson UK
G Williams UK
Z Wu Germany
P Yoo UK
B Yildiz Turkey
J Young France
C Zolin
M Zatelli Italy
H Lehnert Germany

The abstracts were marked by the Abstract marking Panel selected by the programme Organising Committee.
The ESE would like to thank its Corporate Members and the ECE 2018 sponsors

**ECE Corporate Members**

**Premium Corporate Members**
- Ipsen
- Pfizer
- Shire Services BVBA

**Corporate Members**
- Laboratoire HRA Pharma
- Novartis Pharmaceuticals
- Novo Nordisk
- Otsuka Pharmaceuticals Europe Ltd
- Sandoz International Gmbh
- Siemens-Healthineers
- Strongbridge Biopharma

**Gold Sponsors**
- Ipsen
- Pfizer
- Novartis Pharmaceuticals

---

**ECE Office**

- Contact: Andrea Davis
- Tel: +44 (0)1454 642247
- Fax: +44 (0)1454 642222
- E-mail: info@euro-endo.org
- Web site: www.ese-hormones.org

- Euro House
- 22 Apex Court
- Woodlands
- Bradley Stoke
- Bristol BS32 4JT, UK

---

**ECE 2016 Secretariat**

- Contact: Niki Cripps
- Tel: +44 (0)1454 640467
- Fax: +44 (0)1454 642222
- E-mail: ece2016@bioscientifica.com
- Website: http://www.bioscientifica.com

- Bioscientifica Ltd
- Euro House, 22 Apex Court
- Woodlands
- Bradley Stoke
- Bristol BS32 4JT, UK
CONTENTS

20th European Congress of Endocrinology 2018

PRIZE LECTURES AND BIOGRAPHICAL NOTES
The European Journal of Endocrinology Prize Lecture ............................................................ EJE1
The Geoffrey Harris Prize Lecture ......................................................................................... GH1
European Hormone Medal Lecture ....................................................................................... EHM1
Clinical Endocrinology Trust Lecture ................................................................................ ECT1

PLENARY LECTURES
Contraception: Past and future ........................................................................................ PL1
Bone regulates the Brain .................................................................................................... PL2
The wonder world of GnRH neurons ................................................................................ PL3
The Retina as a Window for Exploring the Brain in Diabetes ................................................ PL4
The link between insulin and fatty liver ............................................................................ PL5
Does therapy for thyroid dysfunction decrease mortality? ............................................... PL6
Metabolic control of longevity .......................................................................................... PL7

SYMPOSIA
Predicting events in autoimmune thyroid disease .......................................................... S1.1–S1.3
Salt & Sweet .................................................................................................................... S2.1–S2.3
Bile Acid & Microbiota (Endorsed by Endocrine Connections) ........................................ S3.1–S3.3
Environmental effects on endocrine functions ................................................................ S4.1–S4.3
The role of sperm epigenome in fertility and inheritance ................................................ S5.1–S5.3
Precision Medicine for diabetes (Endorsed by the European Journal of Endocrinology) S6.1–S6.3
Expanding the spectrum of thyroid hormone use (Endorsed by the European Journal of Endocrinology) S7.1–S7.3
Bone fragility – from bench to clinic ............................................................................. S8.1–S8.3
EAA /ESE Session: Male gonadal function versus general health and vice versa .......... S9.1–S9.3
Hot topics in NETs .......................................................................................................... S10.1–S10.3
Novel aspects of Craniopharyngioma ............................................................................. S11.1–S11.3
Why do fractures occur in endocrine disorders, and how should they be handled? .... S12.1–S12.3
The colours of fat .......................................................................................................... S13.1–S13.3
Neuroendocrine basis of reproductive disorders .......................................................... S14.1–S14.3
EYES: New aspects in the study of neuroendocrine diseases ......................................... S15.1–S15.6
Changing practice in the management of thyroid neoplasms ........................................ S16.1–S16.3
Recent advances in Primary Adrenal Macronodular Hyperplasia ................................. S17.1–S17.3
Borderline testosterone and metabolic outcomes among sexes: clinical relevance ...... S18.1–S18.3
New Aspects of Pituitary Regulation ............................................................................. S19.1–S19.3
All you need to know about lipodystrophy (Endorsed by Endocrine Connections) .... S20.1–S20.3
The Dance of Adrenal and Gonads (Endorsed by Endocrine Connections) ................ S21.1–S21.3
The fatty bone .............................................................................................................. S22.1–S22.3
Pre-diabetes .................................................................................................................. S23.1–S23.3
Ups and downs of hypothalamo-pituitary hormones .................................................... S24.1–S24.3
Late Breaking ................................................................................................................. S25.1–S25.3
Cortisol: Too much of a Good Thing ............................................................................. S26.1–S26.3
Emerging treatments in osteoporosis ............................................................................. S27.1–S27.3
Endocrinology Meets Immunology ............................................................................... S28.1–S28.3
Thyroid hormone action: regulation and clinical implications ..................................... S29.1–S29.3
Disorders of Sexual Development (DSD) ..................................................................... S30.1–S30.3
Special Symposium: Bone & Vitamin D (Endorsed by Endocrine Connections) ........ S31.1–S31.3
Guidelines: ESE - ENSAT guidelines on the management of adrenocortical carcinoma in adults GL1.1–GL1.6
Endo-ERN: concrete examples of added value for patient care ................................... ERN1.1–ERN1.3
POSTER PRESENTATIONS: ENVIRONMENT, SOCIETY AND GOVERNANCE

Diabetes therapy ................................................................. P613
Endocrine Disruptors .......................................................... P614–P615
Neuroendocrinology ............................................................ P616
Pituitary - Clinical ................................................................. P617
Thyroid (non-cancer) .............................................................. P618–P620

POSTER PRESENTATIONS: INTERDISCIPLINARY ENDOCRINOLOGY

Adrenal cortex (to include Cushing’s) ......................................... P621–P622
Calcium & Vitamin D metabolism ........................................... P623
Cardiovascular Endocrinology and Lipid Metabolism ..................... P624–P629
Clinical case reports - Pituitary/Adrenal .................................... P630–P631
Clinical case reports - Thyroid/Others ..................................... P632–P636
Developmental endocrinology .............................................. P637
Diabetes (to include epidemiology, pathophysiology) ..................... P638–P642
Endocrine Disruptors ............................................................. P643–P645
Endocrine tumours and neoplasia .......................................... P646–P656
Female Reproduction ........................................................... P657–P662
Growth hormone IGF axis - basic ........................................... P663–P665
Neuroendocrinology .............................................................. P666–P672
Nuclear receptors and Signal transduction ................................ P673–P675
Obesity .............................................................................. P676
Paediatric endocrinology ..................................................... P677–P679
Steroid metabolism + action ................................................ P680–P682
Thyroid (non-cancer) ............................................................ P683–P684
Thyroid cancer .................................................................. P685

POSTER PRESENTATIONS: PITUITARY AND NEUROENDOCRINOLOGY

Adrenal cortex (to include Cushing’s) ......................................... P686–P689
Clinical case reports - Pituitary/Adrenal .................................... P690–P727
Developmental endocrinology .............................................. P728
Endocrine Nursing ............................................................... P729
Endocrine tumours and neoplasia .......................................... P730–P736
Female Reproduction ........................................................... P737–P738
Growth hormone IGF axis - basic ........................................... P739–P742
Neuroendocrinology .............................................................. P743–P770
Paediatric endocrinology ..................................................... P771–P775
Pituitary - Basic ................................................................. P776–P787
Pituitary - Clinical ................................................................. P788–P888

POSTER PRESENTATIONS: REPRODUCTIVE ENDOCRINOLOGY

Adrenal cortex (to include Cushing’s) ......................................... P889
Bone & Osteoporosis ............................................................. P890
Cardiovascular Endocrinology and Lipid Metabolism ..................... P891–P892
Clinical case reports - Thyroid/Others .................................... P893–P898
Developmental endocrinology .............................................. P899–P901
Diabetes (to include epidemiology, pathophysiology) ..................... P902
Endocrine Disruptors ............................................................. P903–P907
Endocrine Nursing ............................................................... P908–P909
Endocrine tumours and neoplasia .......................................... P910
Female Reproduction ........................................................... P911–P958
Male Reproduction ............................................................. P959–P975
Neuroendocrinology .............................................................. P976
Paediatric endocrinology ..................................................... P977–P979
Pituitary - Basic ................................................................. P980
Steroid metabolism + action .......................... P981–P983
Thyroid (non-cancer) ........................................... P984

POSTER PRESENTATIONS: THYROID
Clinical case reports - Thyroid/Others ........................ P985–P1005
Developmental endocrinology .................................. P1006
Endocrine Disruptors .................................................. P1007–P1008
Endocrine tumours and neoplasia ............................... P1009–P1010
Nuclear receptors and signal transduction ......................... P1011
Paediatric endocrinology ........................................... P1012
Thyroid (non-cancer) ...................................................... P1013–P1117
Thyroid cancer .......................................................... P1118–P1205

ePOSTER PRESENTATIONS
Adrenal and Neuroendocrine Tumours ........................ EP1–EP28
Calcium and Bone ....................................................... EP29–EP34
Diabetes, Obesity and Metabolism ................................ EP35–EP90
Interdisciplinary endocrinology .................................... EP100–EP135
Reproductive Endocrinology ........................................ EP155–EP191
Thyroid ................................................................. EP155–EP191

INDEX OF AUTHORS
Poster Presentations: Pituitary and Neuroendocrinology
P744

Clinical and radiological characteristics of patients with primary empty sella
Rym Belaid1, Nadia Mchirgu1, Imen Rojbi1, Amel Jaidane2, Itissem Ben Nacer1, Karima Khair1, Haroun Ouertani1 & Néjib Ben Abdallah1
1Department of Endocrinology, Internal Medicine A, Charles Nicolle’s Hospital, Tunis, Tunisia; 2Department of Endocrinology, Military Hospital, Tunis, Tunisia.

Background
The primary empty sella (PES) is radiologically defined as partial when less than 50% of the sella is filled with cerebrospinal fluid (CSF) and pituitary gland thickness is ≥3 mm or total when more than 50% of the sella is filled with CSF and the gland thickness is ≤2 mm in diameter. The aim of our study was to evaluate clinical and radiological aspects of PES.

Methods
We retrospectively evaluated clinical features and radiological findings of 36 patients with PES followed in the internal medicine department of the Charles Nicolle’s hospital and the endocrinology department of the Military hospital of Tunis between 1992 and 2016.

Results
Our study included 26 women and 10 men with an average age of 47.64 ± 15.47 years [9–83]. Of the risk factors of PES, multiparity was detected in 76% of the whole female patients. Obesity, hypertension, diabetes mellitus and autoimmune hypothyroidism were found in 41.6%, 38.9%, 27.8% and 8.3% of the whole study group, respectively. Only one patient had idiopathic intracranial hypertension. Endocrine signs were the most common presenting symptoms (52.7%).

Conclusion
The diagnosis must be evoked in a middle-aged, obese, multiparous and hypertensive woman presenting with a symptomatology suggestive of pituitary insufficiency or chronic headache.

P746

Sox 2 expression in human pituitary adenomas—correlations with pituitary function
Cristina Capatina1, Anca Cimpanianu2, Marius Raica3, Mihai Coculescu1 & Catalina Povaina1
1Carol Davila UMF, Department of Endocrinology, Bucharest, Romania; 2C.I. Parhon National Institute of Endocrinology, Bucharest, Romania; 3Victor Babes UMF, Timisoara, Romania.

Introduction
Sox2 is a widely expressed marker of progenitor and stem cells in various organs, strongly expressed within Rathke’s pouch and the neural ectoderm. It exerts a critical role in the early stages of pituitary development but it is still expressed in the adult gland. Sox2 expression in pituitary adenomas and its possible correlation with clinicopathologic characteristics have not been investigated so far.

Aim
To evaluate the immunohistochemical expression of Sox2 protein in pituitary adenomas.

Subjects and methods
We included in the study 34 pituitary adenoma samples (13 GH-secreting, ten prolactinomas with proven resistance to dopamine agonists and 10 non-functioning adenomas) prelevated at the time of the neurosurgical intervention. Tissue samples were analyzed by immunohistochemistry for pituitary hormones and Sox2 expression by the avidin-biotin-HRP method.

Results
Sox2 positive expression was detected in 16 patients (47.05% of cases) and did not show an association with tumor volume or extension at diagnosis. GH-secreting tumors were immunopositive for Sox2 in 57.14% of cases, prolactinomas in 60% and non-functioning pituitary adenomas in only 20% of cases (significantly higher percentage of Sox2 positivity among secreting tumors, P = 0.041). 58.82% of all patients (20 cases) had pituitary insufficiency at diagnosis. At diagnosis, the percentage of corticotrophin and gonadotrophin deficiency was significantly higher in patients with Sox2 negative tumors compared to those with Sox2 positive tumors (P = 0.047 and 0.041, respectively).

Conclusion
Sox2 positive expression is frequent in pituitary adenomas (especially in secreting tumors) but is not correlated to tumor size or invasiveness. However, intratumoral Sox2 expression is associated at the Mesoanterior pituitary lobe, with a lower percentage of pituitary insufficiency.

Statistical analysis
Parameters were not normally distributed and Kruskal-Wallis test, followed by Dunn’s test, was used to compare continuous variables. Correlations were performed using linear regression models.

Results
8101 records (5454 from males and 2647 from females) of serum sodium (mean 139.4 ± 3.1 mEq/l) evaluated in HIV-infected patients (mean age 49.0 ± 7.9 years) were considered. 617 (7.6%) HypoNa, 44 (0.5%) HyperNa and 7440 (91.8%) NormoNa were found. Frailty score was inversely related to serum sodium (r = −0.174, R2 = 0.03, P < 0.0001), even after the exclusion of HypoNa group (r = −0.191, R2 = 0.036, P < 0.0001). Frailty was significantly higher in HypoNa than NormoNa (P < 0.001). Considering results at DXA examination, BMD was normal in 30.3% and reduced in 69.7% (54.8% osteopenia, 14.9% osteoporosis). Total body BMD, but not femoral nor lumbar, directly correlated with serum sodium (R = 0.049, P < 0.001) and it was significantly lower in HypoNa compared to NormoNa (P = 0.029).

Conclusions
This study shows that serum sodium is inversely related to frailty, suggesting its potential role as reliable and cheap marker in the HIV-infection follow-up. Furthermore, we demonstrate a direct correlation between sodium and body BMD in HIV-infected patients, similarly to general population.

DOI: 10.1530/endoabs.56.P746
Author Index

Álvarez Escolá, C GP11
Álvarez Hernández, J GP145
Álvarez Segurola, C P50
Álvarez, V GP231
Álvarez Vaz, A GP67
Álvarez-de Frutos, V P334
Álvarez-Éscolá, C GP199
Ávila Mendoza, J P778
Ávila-Rubio, V P310, P383
Aancute, A P185
Aaseth, E P216
Aasheim, E P216
Abad González, AL GP212
Abbara, A OC2.1
Abbas, A P44
Abbas, W EP111
Abd e-Imolhsen, E P1069
Abd El-salam, RF P335
Abdel El Kawi, N EP154
Abdelhamid, A GP250
Abdelhedi, F EP103
Abdelmoula, J P295
Abdelsalam, M P220
Abdi, A EP97, EP98
Abduljabbar, R P1014
Abulladjananova, N GP112
Abduvalieev, A P565
Abe, M P743
Aberer, F P308
Abibova, I GP176
Abid, K P624, P648
Abid, m P1109, P144
Abid, N P343
Aboelazayed, S P220
Aboishava, L GP91
Aboisi-Appeadu, K P366
Aboishava, L GP91
Aboishava, L GP91
Abid, m P1109, P144
Abid, N P343
Aboelazayed, S P220
Aboishava, L GP91
Aboisi-Appeadu, K P366
Abrahamsen, B GP127
Abraïtine, A EP100, EP101
Abreu, A P993
Abreu Lomba, A EP187, P38
Abrosimov, A P1134
Abuin, J EP31, P805, P836
Abusahmin, H P358
Abusoglu, S P350, P625, P988
Abuzahab, MJ P849
Acedo, R P1203
Ach, K EP153
Ach, K P162, P409, P971, P802, P87
Ach, MT P791
Ach, T P162, P409, P802
Acosta Calero, C EP28
Acosta-Calero, C EP69, P18, P262, P293, P76, P79
Adas, M P1042
Adamcová, K P932
Adamidou, F GP192, P689, P868
Adamo, M OC6.2
Adamopoulos, CG P87
Adamski, J P1040
Adank, Muriel A P955
Adelantado, JM P776
Adesanya, O P141
Adzerinho, J P298
Afanasyev, NG GP173, P352
Afonso, C P728
Afonso Martin, JL GP16
Agarwal, A P210
Agarwal, a P6
Agarwal, g P6
Agate, L P1154
Agea Diaz, L P147
Agea, L P846
Aggeli, CG P353
Agga, A EP116, P811
Aghajanov, Y EP66, P979
Agic, S P502
Aglaina, Z P20
Agnarsson, BA GP28
Agnew, L P969
Agorianniis, G OC10.2
Agostini, L GP114
Agraval, D P218
Agreda, J P138
Aguaio Garcia, RG P258
Aguiar Moreira, C P199
Aguilas Diosado, M GP14, P526, P549, P567, P639
Aguilar-Soler, G GP150
Aguilera Venegas, IG P330
Aguilar Diosado, M P568
Aguirre Moreno, N P49
Aguirre, M GP237
Aguirre Moreno, N P1166
Aguirre Moreno, N P1078, P1192, P740
Ahmad, A P1014
Ahmad, I P668
Ahmad, MS P669
Ahmed, A P55
Ahmed, F GP175
Ahmed, H P332
Ahmed, I P669
Ahmed, L P1119
Ahmed, M P395
Ahmed, MS P668
Ahsan, SF P677
Ahetov, I P396, P504
Ahn, C GP107, P527
Ahn, CW P296, P359, P360, P560
Ahn, KJ P501
Aida, C P408
Aimaretti, G P616
Ainsworth, M P306
Aissouali, D P466
Ajdžanović, V GP246
Ajdžanovic, V GP246
Ajilj, R P144
Ak Sivrikoz, I P148
Akalin, A P1150, P148
Akama, Y EP3
Akersu, c P1022
Akay, F P1016
Abay, E P477, P826
Akceke, F P289
Akgür, S GP75, P217, P320, P434, P442, P641, P848, P991
Akgul, G EP92
Akhmadiev, E EP160, EP183
Akincl, B GP59
Akirov, A GP79
Akkan, T P1064
Akker, S P1160
Akku, ON P962
Aksan, S P1085
Aksionova, E P608
Aktas, N EP50
Akteurk, M P307
Akteurk, M P1085, P325, P467, P711
Akyav, Z GP108
Akyurek, F P625
Al Bashir, S P972
Al Mandhari, A EP99
Al Nasser, A P1107
Alaguney, ES P1150, P22
Al-Alawi, K EP99
Al-Atwan, H EP22, P97
Alba-Loureiro, TC P583
Albani, A GP197
Alberiche, MP P958
Alberiche Ruano, M del P P1056
Albersen, M P960
Albert Fábregas, L OC14.5
Albert, L P27, P389, P391
Albu, A P123, P90
Albu, A P94
Albuquerque, L GP208, P867, P882, P888
Alcaide, C OC3.3
Alcaide-Torres, J P585
Alcaina, Y OC9.1
Alcaide, J P1048
Alchujyan, N EP66
Alcântara Laguna, M P1070
Alcântara Laguna, MG P374
Alcubierre, NG P101
Alcázar Lázaro, V OC1.2
Aldiss, P GP160
Alecrit, A EP12
Alejo, A P164, P292
Alejo, M P303
Alejo Ramos, M GP258
Aleksandrov, Y EP162, P1045
Aleric, I GP39
Alexianu, M GP264, P1143
Alexianu, M P742
Alexander, Y P453, P455
Alexander, Y P453, P455
Alexandraki, K GP87, P141, P142, P143, P525
Alexiu, I GP127
Afsolt, M P972
Aliafiq, MA P640
Al Ío, J GP237
Al Faro Martínez, JJ GP13
Alhambra Expósito, MR P1070, P374